Association of depressive symptoms with cognitive impairment in patients with never-treated first-episode schizophrenia: Analysis of the Depression in Schizophrenia in China (DISC) study

Chen, Xi Jing; Wang, Dong Mei; Zhou, Hui; Zhu, Rong; Tian, Yang; Du, Yu Xuan; Chen, Jia Jing; Chen, Da Chun; Wang, Li; Zhang, Xiang Yang

doi:10.1016/j.genhosppsych.2021.04.010

Cited by 6 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, psychiatrists pay more attention and importance to positive, negative, and cognitive symptoms, but the incidence rate of depression is high in various stages of schizophrenia. A domestic study demonstrated that 49.37% of patients with first-episode schizophrenia presented depressive symptoms [ 2 ]. There is a higher incidence rate of depression in elderly patients with schizophrenia spectrum disorders (SSD).…”

Section: Introductionmentioning

confidence: 99%

“…A part of previous studies revealed the clinical risk factors and possible pathophysiological mechanisms of depression and impulse in schizophrenia. The depressive symptoms of schizophrenic patients are associated with an early onset age, serious negative symptoms, serious common psychotic symptoms, akathisia, dyskinesia [ 11 ], cognitive impairment [ 2 ], high serum LDL and TC levels [ 12 ], and even insomnia [ 13 ]. Schizophrenic impulse is related to frontotemporal circuit dysfunction [ 14 ] and cortical thickness [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Study on correlations of BDNF, PI3K, AKT and CREB levels with depressive emotion and impulsive behaviors in drug-naïve patients with first-episode schizophrenia

Kang

et al. 2023

BMC Psychiatry

View full text Add to dashboard Cite

Background The pathogenesis of schizophrenia is still unknown. Nearly a half of schizophrenic patients have depressive symptoms and even some impulsive behaviors. The definite diagnosis of schizophrenia is an immense challenge. Molecular biology plays an essential role in the research on the pathogenesis of schizophrenia. Objective This study aims to analyze the correlations of serum protein factor levels with depressive emotion and impulsive behaviors in drug-naïve patients with first-episode schizophrenia. Methods Seventy drug-naïve patients with first-episode schizophrenia and sixty-nine healthy volunteers from the health check center in the same period participated in this study. In both the patient group and control group, brain-derived neurotrophic factor (BDNF), phosphatidylin-ositol-3-kinase (PI3K), protein kinase B (AKT), and cAMP-response element binding protein (CREB) levels in the peripheral blood were tested by enzyme-linked immunosorbent assay (ELISA). The depressive emotion and impulsive behaviors were evaluated with Chinese versions of the Calgary Depression Scale for Schizophrenia (CDSS) and Short UPPS-P Impulsive Behavior Scale (S-UPPS-P), respectively. Results The serum levels of BDNF, PI3K, and CREB in the patient group were lower than those in the control group, while AKT level, total CDSS score and total S-UPPS-P score were all higher. In the patient group, total CDSS score, and total S-UPPS-P score were both correlated negatively with BDNF, PI3K, and CREB levels but positively with AKT level, and the lack-of-premeditation (PR) sub-scale score was not significantly correlated with BDNF, PI3K, AKT, and CREB levels. Conclusion Our study results showed that the peripheral blood levels of BDNF, PI3K, AKT, and CREB in drug-naïve patients with first-episode schizophrenia were significantly different from those in the control group. The levels of these serum protein factors are promising biomarkers to predict schizophrenic depression and impulsive behaviors.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Study on correlations of BDNF, PI3K, AKT and CREB levels with depressive emotion and impulsive behaviors in drug-naïve patients with first-episode schizophrenia

Kang

et al. 2023

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…Inclusion criteria were: (1) specialist help-seeking request; (2) age between 12 and 35 years; (3) presence of FES in accordance with the DSM-IV-TR diagnostic criteria [10]; and (4) a DUP (i.e. "Duration of Untreated Psychosis" defined as the time interval [in weeks] between the onset of fullblown psychotic symptoms and the first antipsychotic intake) [11] of < 2 years.…”

Section: Setting and Subjectsmentioning

confidence: 99%

“…Depressive psychopathology is a frequent comorbid condition in First Episode Schizophrenia (FES) [1]. In particular, clinically relevant Depressed Mood (DM) in FES seems to be significantly related to poor real-world performance [2] and is one of the stronger predictors for suicidal thinking and behavior, even more than command hallucinations [3]. However, DM is still often overlooked in the clinical practice with young people with FES, also due to the greater importance attributed to positive and negative Archives of Psychiatry and Psychotherapy, 2023; 2: 15-24 symptoms, and to the uncertainty on its clinical significance and etiopathogenesis [4].…”

Section: Introductionmentioning

confidence: 99%

Is depressed mood clinically relevant at the onset of schizophrenia? A longitudinal study.

Pelizza¹,

Leuci²,

Quattrone³

et al. 2023

Arch Psych Psych

View full text Add to dashboard Cite

Aim of the studyThe aims of this investigation were: (1) to calculate baseline prevalence of FES patients with relevant depressed mood (DM), (2) to longitudinally monitor DM levels over a 12-month follow-up, and (3) to investigate their associations with clinical data and the specific treatment components of an “Early Intervention in Psychosis” (EIP) program.Subject or material and methodsThe Positive And Negative Syndrome Scale (PANSS) was completed by all FES participant. Individuals with a baseline PANSS “Depression” item subscore of ≥ 5 were classified as having relevant depressed mood (FES/DM+). Chi-square and Mann-Whitney tests were used for inter-group comparisons. A linear regression analysis was also performed.ResultsFifty-three (33.3%) participants were in the FES/DM+ subgroup. Relevant baseline DM at baseline was associated with female gender and a higher PANSS “Positive Symptoms” score. Across the follow-up, FES individuals improved their DM levels. This was significantly related to a longitudinal decrease in PANSS “Positive Symptoms” levels.DiscussionMore than 1/3 of FES subjects had relevant DM already at the recruitment time in an EIP service. This suggests that relevant depression in FES subjects is usually under-treated. Moreover, we observed a significant decrease in DM severity levels across the follow-up. This decrease was associated with the longitudinal severity reduction in positive symptom levels, reflecting their state-related fluctuations.ConclusionsDM is relatively frequent in FES, already at the recruitment in EIP services. However, its severity decreases overtime within specialized EIP programs.

show abstract

Rumination mediates the relationship between childhood trauma and depressive symptoms in schizophrenia patients

Fang

Wen

et al. 2022

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Association of depressive symptoms with cognitive impairment in patients with never-treated first-episode schizophrenia: Analysis of the Depression in Schizophrenia in China (DISC) study

Cited by 6 publications

References 53 publications

Study on correlations of BDNF, PI3K, AKT and CREB levels with depressive emotion and impulsive behaviors in drug-naïve patients with first-episode schizophrenia

Study on correlations of BDNF, PI3K, AKT and CREB levels with depressive emotion and impulsive behaviors in drug-naïve patients with first-episode schizophrenia

Is depressed mood clinically relevant at the onset of schizophrenia? A longitudinal study.

Rumination mediates the relationship between childhood trauma and depressive symptoms in schizophrenia patients

Contact Info

Product

Resources

About